Skip to main content
Article thumbnail
Location of Repository

An overview of pharmaceutical policy in four countries: France, Germany, the Netherlands and the United Kingdom

By Elias Mossialos and Adam Oliver

Abstract

The regulation of pharmaceutical markets is an important policy concern in many countries, and is generally undertaken with cost containment, efficiency, quality and equity objectives in mind. This article presents an overview of the demand-side and supply-side regulatory measures that have been introduced in four European countries, namely France, Germany, the Netherlands and the United Kingdom. More specifically, after considering some of the trends in pharmaceutical expenditure in these four countries over recent decades, the article considers the policies that have been introduced to influence patient demand, health care provider behaviour and the pharmaceutical industry. Since many of the policies are concurrently applied, it is difficult to assess the isolated impact of each, particularly because the effect of particular policies may often be country specific. However, it is clear that there is no overriding perfect solution to balancing the cost containment, efficiency, quality and equity objectives in pharmaceutical policy. No one policy or policy combination is right for all countries, and different countries will need to meet their own objectives through policy approaches that reflect their own particular environment

Topics: H Social Sciences (General), RA Public aspects of medicine
Publisher: John Wiley and Sons, Ltd
Year: 2005
DOI identifier: 10.1002/hpm.816
OAI identifier: oai:eprints.lse.ac.uk:19664
Provided by: LSE Research Online
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www3.interscience.wiley... (external link)
  • http://eprints.lse.ac.uk/19664... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.